Newron Pharmaceuticals SpA Share Price CBOE EUROPE EQUITIES
Equities
0QOI
IT0004147952
Pharmaceuticals
End-of-day quote
Other stock markets
|
||
- CHF | - |
Sales 2024 * | 35.98M 38.52M 35.12M 3.21B | Sales 2025 * | 25.95M 27.79M 25.33M 2.32B | Capitalization | 156M 167M 152M 13.94B |
---|---|---|---|---|---|
Net income 2024 * | 7M 7.49M 6.83M 625M | Net income 2025 * | 4M 4.28M 3.9M 357M | EV / Sales 2024 * | 5.15 x |
Net Debt 2024 * | 29.11M 31.16M 28.42M 2.6B | Net Debt 2025 * | 2M 2.14M 1.95M 179M | EV / Sales 2025 * | 6.09 x |
P/E ratio 2024 * |
10.7
x | P/E ratio 2025 * |
35.9
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.61% |
Latest transcript on Newron Pharmaceuticals SpA
Managers | Title | Age | Since |
---|---|---|---|
Stefan Weber
CEO | Chief Executive Officer | 60 | 15/12/15 |
Luca Benatti
FOU | Founder | 63 | 01/98/01 |
Roberto Galli
DFI | Director of Finance/CFO | - | 01/02/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 78 | 01/08/01 | |
Luca Benatti
FOU | Founder | 63 | 01/98/01 |
Ulrich Köstlin
CHM | Chairman | 71 | 01/13/01 |
1st Jan change | Capi. | |
---|---|---|
-3.93% | 86.16B | |
+2.76% | 40.17B | |
-16.69% | 31.47B | |
+54.44% | 25.24B | |
-12.30% | 15.82B | |
-9.12% | 11.96B | |
-15.73% | 11.89B | |
-42.56% | 11.61B | |
+4.87% | 8.84B |
- Stock Market
- Equities
- NWRN Stock
- 0QOI Stock